Clinical trials: Breast Cancer (Early Breast Cancer)
Triple Negative Breast Cancer
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
Eligible patients with stage 2 and 3 triple negative breast cancer will be treated with 4 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab. A PET scan will be performed at baseline and after 1 cycle of therapy.
- Trial name
- NeoADAPT (NCT06245889)
- Testing
- Paclitaxel, Carboplatin, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET
The main purpose of follow-up in asymptomatic breast cancer patients during and after adjuvant treatment is to detect breast cancer recurrence and metastatic disease.The aim of this trial is to verify if, in asymptomatic…
- Trial name
- NCT02261389
- Testing
- Arm B, tumor markers assessment
- Where
- 7 sites in Italy
- Volunteers
- 1,507 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer
Phase II Study of Single Agent Lenvatinib
The Investigators hypothesize that single agent lenvatinib has biological activity in estrogen receptor positive breast cancer, and that the effects are more pronounced in patients with positive RET expression in the tumor.
- Trial name
- NCT03168074
- Testing
- lenvatinib
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer
Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology
This study will evaluate LumaScan, an innovative polarization microscope for real time, intraoperative imaging and evaluation of the surface of excised tissue excised during Breast Conservation Surgery (BCS) for non invasive and…
- Trial name
- NCT02207179
- Testing
- LumaScan Image Guided Surgery
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- LumaMed
Early-Stage Breast Cancer
Cryoablation Versus Lumpectomy in Early-Stage Breast Cancer
The goal of this randomised controlled trial is to compare ipsilateral breast cancer recurrence rates in patients with early-stage breast cancer between patients treated with breast conserving surgery and patient treated with…
- Trial name
- CRYSTAL (NCT07483996)
- Testing
- Percutaneous cryoablation, Breast-conserving surgery
- Volunteers
- 938 people
- Sponsor
- Franciscus Gasthuis & Vlietland (Hospital)
Breast Cancer, Neoadjuvant Therapy
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4).
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706
- Trial name
- NCT07372079
- Testing
- QL1706 combined with Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Exercise During Chemotherapy in Older Women With Stage I-III Breast Cancer
This clinical trial evaluates the feasibility of exercise during chemotherapy in older women with stage I-III breast cancer. Previous studies have reported that exercise may reduce the chemotherapy-toxicity risk.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT05025059
- Testing
- Discussion, Exercise Intervention, Informational Intervention
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
HER2 Positive Early or Locally Advanced Breast Cancer
A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly…
- Trial name
- NCT02149524
- Testing
- Herceptin (trastuzuamb), SB3 (proposed trastuzumab biosimilar)
- Where
- Czechia
- Volunteers
- 875 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Chemotherapy Adjuvant, Breast Cancer
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
The efficacy and safety of the Dignicap System to prevent chemotherapy induced alopecia will be evaluated in women with early breast cancer undergoing adjuvant or neoadjuvant chemotherapy regimens.
- Trial name
- NCT01831024
- Testing
- Dignicap System
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Target Health Inc.
Metastatic Triple Negative Breast Cancer
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer
The study hypothesise that the combination of carboplatin, gemcitabine, bevacizumab and atezolizumab may be synergistic and improve outcomes for patients with early relapsed TNBC by overcoming mechanisms of immune resistance and…
- Trial name
- BELLA (NCT04739670)
- Testing
- Atezolizumab, Bevacizumab, Gemcitabine
- Where
- 4 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy
CIPN in Early Stage Breast Cancer Patients
Chemotherapy uses anti-cancer drugs to destroy cancer cells and is a common treatment for many cancers. Taxanes are the most widely used chemotherapy drugs given to breast cancer patients.
- Trial name
- NCT05441722
- Testing
- Exercise prehabilitation
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- Northumbria University
Breast Neoplasms, Neoplasm Recurrence, Local
Accelerated Partial Breast Irradiation With IMRT in Early Breast Cancer
This study is to evaluate the efficacy and toxicity of accelerated partial breast irradiation (ABPI) with intensity modulated radiation therapy (IMRT) in low-risk breast cancer treat with breast-conserving surgery.
- Trial name
- NCT03583580
- Testing
- Accelerated Partial Breast Irradiation
- Where
- China
- Volunteers
- 537 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer, Early-stage Breast Cancer
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
In this research study, investigators are testing if a dose-increasing strategy for abemaciclib will have less side effects and be better tolerated than the standard dosage of abemaciclib for participants with early-stage…
- Conditions
- Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
- Trial name
- NCT06001762
- Testing
- Abemaciclib, Tamoxifen, Anastrozole
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer
The primary objective of this trial is to evaluate the effect of the addition of a 2 year, centrally delivered individualized, telephone-based lifestyle intervention focusing on weight management to a mailed educational…
- Trial name
- LISA (NCT00463489)
- Testing
- Lifestyle intervention, Mail-based
- Where
- 21 sites in United States, Canada
- Volunteers
- 338 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer
Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer
This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients…
- Trial name
- EUTACAM (NCT04740697)
- Testing
- Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Institut Claudius Regaud
Breast Cancer, HER2-negative Breast Cancer
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer, Breast Carcinoma
- Trial name
- NCT05150652
- Testing
- Anastrozole 1mg, Letrozole 2.5mg, Exemestane 25 mg
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Irada Ibrahim-zada
Breast Cancer
Single-fraction APBI for Early-stage Breast Cancer With Favorable Histological Subtypes (Breast-1F)
This is a prospective, randomized, monocentric, non-inferiority interventional clinical study comparing an Accelerated Partial Breast Irradiation (APBI) for the surgical bed of early-stage breast cancer patients with favorable…
- Trial name
- Breast-1F (NCT06946238)
- Testing
- Adjuvant single-fraction accelerated partial breast irradiation
- Where
- Italy
- Volunteers
- 311 people
- Sponsor
- IRCCS San Raffaele
Breast Cancer
Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
The aim of this study was to describe the epidemiology, treatment pathway, treatment access, wastage of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), and health care resource use among adults with hormone receptor positive…
- Trial name
- ROTOR (NCT07498413)
- Where
- United Kingdom
- Volunteers
- 218,677 people
- Sponsor
- Novartis Pharmaceuticals
Triple Negative Breast Cancer, Breast Cancer
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from…
- Trial name
- NCT04768426
- Testing
- Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Malignant Tumor of Breast
Lifestyles and Breast Cancer
Background: In Spain, 1 out of every 11 women will have a breast cancer before the age of 85 years and breast cancer is the leading cause of potential years of life lost.
- Trial name
- LifeBreast (NCT04174391)
- Testing
- Mediterranean diet supplemented with extra-virgin olive oil, Low-fat diet
- Where
- 4 sites in Spain
- Volunteers
- 766 people
- Sponsor
- University of Navarra
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.